Form 4: Aptevo Therapeutics Director Grant Grady III Acquires Restricted Stock Units

Director Grant Grady III acquired 925 Restricted Stock Units (RSUs) of Aptevo Therapeutics Inc. on July 17, 2024, which will vest in full on the first anniversary of the grant date.

Summary

• On July 17, 2024, Grant Grady III, a director of Aptevo Therapeutics Inc., acquired 925 Restricted Stock Units (RSUs).
• These RSUs convert into common stock of Aptevo Therapeutics on a one-for-one basis.
• The RSUs will vest in full on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of RSUs could be seen as mildly positive, but it's a routine event.

Positives

• The acquisition of RSUs by a director may indicate confidence in the company's future performance.

Future Outlook

The vesting of the RSUs in one year suggests a potential future increase in the director's holdings of Aptevo Therapeutics common stock.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of RSUs, a common form of equity compensation.

Stakeholder Impact

• The acquisition of RSUs by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Aptevo Therapeutics, Grant Grady III, Restricted Stock Units, RSUs, Director, Beneficial Ownership, Form 4, SEC Filing